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Abstract
Introduction: Ketogenic diets have shown to improve glycaemic control in patients 
with type 2 diabetes. This study investigated the safety, tolerability, and effects on 
glycaemic control in patients with type 2 diabetes of an exogenous ketone monoester 
(KE) capable of inducing fasting- like elevations in serum β- hydroxybutyrate (βHB) 
without the need for caloric or carbohydrate restriction.
Methods: Twenty one participants (14 men and 7 women, aged 45 ± 11 years) with 
insulin- independent type 2 diabetes, and unchanged hypoglycaemic medication for 
the previous 6 months, were recruited for this non- randomised interventional study. 
Participants wore intermittent scanning glucose monitors (IS- GM) for a total of 
6	weeks	and	were	given	25	ml	of	KE	3	times	daily	for	4	weeks.	Serum	electrolytes,	
acid- base status, and βHB concentrations were measured weekly and cardiovascular 
risk markers were measured before and after the intervention. The primary endpoints 
were safety and tolerability, with the secondary endpoint being glycaemic control.
Results: The	21	participants	consumed	a	total	of	1,588	drinks	(39.7	litres)	of	KE	over	
the course of the intervention. Adverse reactions were mild and infrequent, includ-
ing mild nausea, headache, and gastric discomfort following fewer than 0.5% of 
the drinks. Serum electrolyte concentrations, acid- base status, and renal function 
remained normal throughout the study. Compared to baseline, exogenous ketosis 
induced a significant decrease in all glycaemic control markers, including fructosa-
mine	(335	±	60	μmol/L	to	290	±	49	μmol/L, p < .01), HbA1c (61 ± 10 mmol/mol to 
55	±	9	mmol/mol	[7.7	±	0.9%	to	7.2	±	0.9%],	p < .01), mean daily glucose (7.8 ± 1.4 mM 
to	 7.4	 ±	 1.3	mM	 [140	 ±	 23	mg/dl	 to	 133	 ±	 25	mg/dl],	p < .01) and time in range 
(67	±	11%	to	69	±	10%,	p < .01).
Conclusions: Constant ketone monoester consumption over 1 month was safe, well 
tolerated, and improved glycaemic control in patients with type 2 diabetes.
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1  |  INTRODUC TION
Exogenous ketosis has therapeutic potential across a diverse range 
of chronic metabolic diseases, including epilepsy, neurodegener-
ative diseases, heart failure and diabetes.1 Very low carbohydrate 
or ketogenic diets can reverse type 2 diabetes,2 and exogenous 
ketosis without carbohydrate restriction lowers blood glucose. As 
examples, d- β- hydroxybutyrate (βHB) salt infusion lowers blood 
glucose in both animals3–	5 and humans.6 Additionally, the con-
sumption of ketone ester (KE)6 or medium chain triglyceride oils5 
lowers blood glucose, suggesting that ketosis itself has a hypo-
glycaemic effect that is independent of carbohydrate restriction.
For reasons that are unknown, the glucose- lowering effect of 
ketosis appears to be greater in patients with type 2 diabetes (T2D) 
than in healthy controls,7 but both insulin dependent8,9 and indepen-
dent10 mechanisms have been proposed. As some patients find car-
bohydrate restriction difficult leading to low long- term adherence11 
and as exogenous ketosis can independently improve glycaemic con-
trol (even after a carbohydrate challenge12), there exists a clinical 
niche for a safe exogenous ketogenic intervention in T2D.
The ketone monoester (KE), (R)-	3-	hydroxybutyl-	(R)-	3-	hydroxy-
butyrate, is a drink that, after ingestion, is cleaved by gut esterases into 
equimolar βHB and (R)-	1,3-	butanediol.	Both	molecules	enter	the	portal	
circulation, and the latter is converted in the liver into βHB.13 Thus, 
each equivalent of KE yields two equivalents of βHB.
The pharmacology and safety of KE has been thoroughly studied 
in animals14 and in healthy human adults.15 However, the safety and 
tolerability of this supplement has not been investigated in patients 
with T2D. Given the metabolic and physiological peculiarities of this 
disease, and the potential benefits of exogenous ketosis on glycae-
mic control, we aimed to study the safety and tolerability of the KE 
in patients with T2D.
The KE is available as a sports supplement16 and carries benefits 
over other ketogenic supplements. First, it provides enantiomerically 
pure d- βHB, which is important because the body primarily uses the 
d form of βHB and not the l enantiomer. Second, it is salt- free and 
so does not impose an undue sodium load, particularly when used 
chronically. Third, KE can raise βHB in blood to fasting- like levels of 
>3	mM	within	minutes.6 Beyond its practical clinical benefits, the KE 
stands out as a research tool for determining the relative contribu-
tions of ketosis versus carbohydrate reduction in a ketogenic diet, 
which can reverse T2D. Thus, the KE could help generate insights 
into disease mechanisms and thereby provide an avenue for devel-
oping targeted therapies.
2  |  METHODS
2.1  |  Ethics approval
The research protocol, including amendments and consent forms, was 
approved by the South Central, Oxford B Research Ethics Committee 
(18/SC/0064). This study was conducted in accordance with the 
guidelines set forth by the International Conference on Harmonization 
Guidelines for Good Clinical Practice, and the Declaration of Helsinki 
regarding the treatment of human subjects in a research study. All 
participants provided written informed consent before their enrol-
ment. This project was registered with the code ISRCTN12401551.
2.2  |  Recruitment and participant characteristics
Potential participants were invited via paper advertisements 
placed on the Warwickshire Institute for the Study of Diabetes, 
Endocrinology and Metabolism (WISDEM). Interested potential 
participants contacted the research team via email to schedule a 
visit to determine eligibility. Recruited were 21 patients with T2D 
aged	18–	70	years	(inclusive)	who	had	no	past	or	present	use	of	insu-
lin to control glycaemia. Participants had no documented changes 
in other hypoglycaemic medications for the 6 months prior to the 
study. If an enrolled participant were prescribed a change in their 
glycaemic treatment during the study, their participation was dis-
continued, and they were excluded from the analysis. Also excluded 
were	patients	with	serum	creatinine	>1.5	mg/dl,	with	elevated	(3x	
the normal upper limit) alanine aminotransferase (ALT) or aspartate 
amino transferase (AST), with scheduled surgical procedures, or 
who were pregnant, lactating or planning to become pregnant.
2.3  |  Study design
Each participant was asked to wear an IS- GM (Abbott FreestyleR; 
Maidenhead, Berks UK ®) for 6 weeks. Week 1 served as a baseline. 
During	weeks	 2–	5,	 participants	were	 asked	 to	measure	 out	 25	ml	
(25 g) of the ketone monoester in a measuring cup and drink it either 
neat or diluted with the zero calorie artificially sweetened drink of 
their choice, three times daily. Figure S1 illustrates these interven-
tions. Participants were also asked to record their meal timings, sleep 
duration, physical activity and symptoms (both positive and negative) 
in a diary. They were instructed to keep their usual diet and physical 
activities throughout the study and to allow at least 4 h between 
KE drinks to elevate serum levels of βHB for at least 12 h every day.
2.4  |  Metabolites and measurements
Tolerability was assessed with self- recorded open adverse effects 
diaries following each of the KE drinks. If an adverse effect was regis-
tered, participants were asked to rank it as ‘mild’, ‘moderate’ or ‘severe’.
Safety was assessed weekly by measuring peak βHB blood levels 
and acid- base balance. For measuring peak βHB levels, participants 
measured their blood βHB using Abbot OptiumNeo® meters imme-
diately	before	and	30	min	following	their	third	KE	drink	on	their	least	
active day of the week.
For assessing acid- base balance, venous blood samples were ana-
lysed weekly for acid- base status, electrolytes, glucose, haemoglobin, 
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serum creatinine and urea (Abbot iSTAT® cartridges CG4± and 
CHEM8±, Abbot Point of Care Inc). Urine was analysed for bilirubin, 
blood, leukocytes, glucose, ketones, nitrite, pH, protein, specific grav-
ity and urobilinogen (Bayer Multistix® Reagent Strips for Urinalysis, 
Bayer HealthCare LLC).
Weekly anthropometric measurements (body weight and body 
composition) and fasting blood and urine samples were collected every 
7 days after enrolment. Body composition was measured using four- 
point bioelectrical impedance scale (BF508®, Omron Electronics Ltd).
Glycaemic control was assessed using (i) blood HbA1c, (ii) blood 
fructosamine, (iii) mean blood glucose and (iv) blood glucose time in 
range. Fructosamine was measured using a semi- automated bench- 
top analyser (ABX Pentra®,	 A11A01679).	 IS-	GM’s	 were	 placed	
on participants 1 week before starting KE supplementation and 
changed every 2 weeks throughout the 6- week trial. Target glucose 
range	was	3.9–	10	mmol/L	(70–	180	mg/dl),	and	time	in	range	was	ob-
tained from the Abbot's Libre View® interface.
For assessing cardiovascular risk, HOMA- IR and 10- year fatal cor-
onary heart disease risk were calculated using open access calcula-
tors available at https://www.dtu.ox.ac.uk/riske ngine/ downl oad.php. 
Additionally, plasma total cholesterol, ApoB, triglycerides, HDL, C- 
reactive protein, and ALT and AST were measured by the Department 
of Clinical Biochemistry at the John Radcliffe Hospital, Oxford, UK.
2.5  |  Sample size rationale
Considering the 1- month duration of the intervention, fructosa-
mine was used for sample size estimation. Other studies report 
that a 15% decrease in fructosamine is clinically relevant.17 
Assuming a standard deviation of 20% and given statistical power 
of 0.80 and alpha of 0.05, 16 participants were required for this 
study. Sample size calculations were performed using G*Power 
Software	version	3.1.18
2.6  |  Analysis
Mean and dispersion values for demographic and biochemical varia-
bles were calculated. Two- tailed Student's t- tests for paired samples 
were used for comparing means. Significance was taken at p < .05. 
Data are presented as mean ± SD. All calculations were performed 
using Microsoft Excel®. There were fewer than 5% missing data 
points, which were handled by mean substitution.
3  |  RESULTS
3.1  |  Participant characteristics
Twenty- three patients were initially enrolled. One participant with-
drew after 1 week without reporting any adverse event. Another 
participant completed 5 weeks of the study but was excluded from 
the analysis because she was prescribed glucocorticoids during 
her last week of the intervention. Therefore, twenty- one partici-
pants (14 males and 7 females), aged 45.1 ± 10.8 years, completed 
the	 study.	 Co-	morbidities	 included	 hypertension	 (38%)	 and	 dys-
lipidaemia (28%). Common glycaemic therapies included metformin 
(90.4%),	liraglutide	(28%)	and	empagliflozin	(19%)	(Table	1).
3.2  |  Tolerability and adherence
All	participants	had	>90%	adherence,	defined	as	consumption	of	at	
least 76 of the maximum 84 KE drinks. Thus, the KE drink was well- 
tolerated. Adverse symptoms were self- recorded by participants 
following each of their drinks and were ranked as ‘mild’, ‘moderate’ 
or ‘severe’. Overall occurrence of adverse symptoms is expressed 
relative to the total number, 1,588, of drinks consumed through-
out	the	entire	study.	Mild	nausea	(5/1,588	=	0.3%),	mild	headache	
(5/1,588	=	0.3%)	and	mild	gastric	discomfort	(9/1,588	=	0.5%)	were	
the only reported symptoms.
3.3  |  Metabolic outcomes and glycaemic control
Blood electrolytes, acid- base status and renal function were normal 
throughout the study. βHB blood concentrations were recorded by 
each	participant	30	min	following	a	25	ml	KE	drink	and	ranged	from	
3.1	±	0.5	mM	to	3.8	±	0.7	mM	(Table	2).
All anthropometric and cardiovascular risk markers were not dif-
ferent	at	baseline	and	follow-	up	(Table	3).
Compared with baseline and follow- up, the KE intervention 
caused a significant decrease in both HbA1c, from 61 ± 10 mmol/
mol	 to	 55	 ±	 9	mmol/mol	 (7.7	 ±	 0.9%	 to	 7.2	 ±	 0.9%)	 (p < .01) and 
TA B L E  1 Participants’	clinical	and	demographic	data
Sex 14 males, 7 females














Concomitant medications 1.7 ± 1.0. Median and 
mode = 1
Note: Data are means ± standard deviation or n (%).
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fructosamine	335	±	60	μM	to	290	±	49	μM (p < .01). Compared to 
baseline and follow- up, exogenous ketosis decreased mean blood 
glucose	 from	 7.8	 ±	 1.4	mM	 to	 7.4	 ±	 1.3	mM	 (140	 ±	 23	mg/dL	 to	
133	±	25	mg/dL)	(p < .01).
The per cent time in range for the blood glucose readings also 
improved significantly during the KE intervention from 67 ± 11% to 
69	±	10%	(p	<	 .01).	Time	above	range	decreased	from	29	±	6%	to	
26 ± 7% (p < .01), and time below range did not change significantly 
3.5	±	0.7%	to	3.6	±	0.9%	(p > .05). Thus, the KE drinks improved all 
four metrics of glycaemic control in 21 patients with T2D (Figure 1).
4  |  DISCUSSION
The primary purpose of this study was to evaluate the safety and 
tolerability of KE drinks in patients with T2D. Since no moderate or 
severe symptoms were recorded, the frequency of any given mild 
symptoms was 0.5% or less, and as no patient experienced sympto-
matic hypoglycaemia, it is reasonable to conclude that the KE is safe 
and well- tolerated. Furthermore, the extremely low number of even 
mild symptoms is congruent with participants’ high adherence to the 
KE drink regimen.
No statistically significant differences were observed in an-
thropomorphic or cardiovascular risk parameters, other than those 
related to glycaemic control. This includes no differences in blood 
pressure, fasting lipid profile, C- reactive protein and body composi-
tion, which contrasts with animal studies that report changes in such 
metrics.19 However, there was a small reduction in total weight of 
1.3	kg	which	could	have	be	greater	with	a	longer-	term	intervention,	
meriting further research. It is worth highlighting that these metrics 
were followed primary for safety purposes and that this study was 
not powered, nor intended to look for, changes in these markers. In 
other words, it is possible that improvements in weight and markers 
other than those related to glycaemic control may have been ob-
served had the intervention lasted longer than 1 month or had a 
larger cohort of patients been studied.
Importantly, all four markers of glycaemic control— HbA1c, 
fructosamine, mean daily blood glucose and time in range— 
improved during sustained exogenous ketosis. HbA1c is the most 
widely used and acknowledged glucose control outcome measure 
in research and clinical practice20 so was important to include in 
this study. However, HbA1c is thought to approximate average 
blood	glucose	over	3	months.	Therefore,	the	6	mmol/mol	improve-
ment observed in HbA1c, while significant, underestimates the 
effect of KE consumption on this parameter. Extrapolating these 
data	 to	 3	months,	 the	magnitude	 of	 the	 effect	 of	 KE	would	 be	
comparable to the decrease in HbA1c achieved by most currently 
prescribed oral hypoglycaemic medications for T2D,21 but is lower 
than what has been observed in studies involving ketogenic diets 
in T2D.2
The shorter half- life of fructosamine, compared to HbA1c, makes 
it a better metric for glycaemic control in interventions lasting less 
than	 3	 months.22 The reduction in fructosamine observed in our 
study,	from	335	to	290	μM, is comparable to the effects of moderate 
to intense exercise interventions. In a study involving eight patients 
with	T2D	who	exercised	at	50%–	60%	VO2	peak	for	30–	60	min	three	
times per week for 8 weeks, fructosamine decreased by 57 μM17 
(compared to 45 μM in this study).
As βHB and exercise likely operate to control glycaemia in T2D 
via complementary mechanisms, the comparison of the KE regimen 
to the effects of exercise is favourable, not only in terms of the ef-
fect of magnitude, but also with respect to the fact that combining 
KE therapy and exercise may have an additive effect on glycaemic 
control. Indeed, recent work has shown that KE is also efficacious 
in improving exercise tolerance in patients with chronic illnesses like 
Parkinson's disease.23
TA B L E  2 Weekly	blood	acid-	base	and	renal	function	assessment
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6
pH 7.39	±	0.03 7.40	±	0.03 7.39	±	0.03 7.40	±	0.03 7.39	±	0.04 7.39	±	0.03
HCO−3 (mM) 23	±	2 23	±	2 22 ± 2 23	±	2 23	±	2 23	±	2
Na+ (mM) 139	±	3 139	±	3 139	±	2 139	±	3 139	±	4 139	±	2
K+ (mM) 4	±	0.3 4.0	±	0.3 4.1	±	0.3 3.9	±	0.3 4.0	±	0.3 3.9	±	0.3
Cl− (mM) 101	±	3 100	±	3 100	±	3 101	±	3 100	±	3 100	±	3
Anion Gap (mEq/L) 15 ± 4 16 ± 5 17	±	3 16 ± 5 16 ± 4 16 ± 4
Creatinine (mg/dL) 1.02 ± 0.17 1.00 ± 0.15 1.01	±	0.13 1.03	±	0.12 1.02 ± 0.15 1.06 ± 0.17
Lactate (mM) 1.7 ± 0.2 1.6 ± 0.1 1.7 ± 0.1 1.7 ± 0.2 1.6 ± 0.2 1.6 ± 0.1
Systolic pressure (mmHg) 125 ± 12 124 ± 10 124 ± 8 125 ± 8 124 ± 12 126 ± 10
Diastolic pressure (mmHg) 83	±	10 83	±	7 83	±	6 85 ± 8 83	±	9 84	±	9
Baseline βHB (mM) NM 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1 NM
30	min	βHB (mM) NM 3.8	±	0.7 3.4	±	0.6 3.1	±	0.5 3.3	±	0.6 NM
Note: Data are means ± standard deviation for n = 21.
Abbreviation: NM, not measured.
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In addition to HbA1c and fructosamine, both blood glucose daily 
mean values and blood glucose time in range exhibited significant 
improvements after sustained exogenous ketosis. The finding that 
all four metrics of glycaemic control reached statistical significance 
strongly suggests that KE is effectively improves glucose control in 
patients with T2D.
The main limitations of this study were the lack of a placebo 
group and the relatively small sample size. A placebo group was not 
included because the primary purpose of this pilot was to demon-
strate the safety and tolerability of KE in patients with T2D. As 
mentioned before, due to the 1- month duration of this study, it was 
not possible to explore potential longer- term glycaemic benefits 
from inducing sustained exogenous ketosis, such as a reduction in 
micro- and macrovascular complications. Additionally, we included 
patients using SGLT2 inhibitors, which have been associated with 
euglycaemic ketoacidosis. The unlikely, but possible, interaction be-
tween these inhibitors and sustained exogenous ketosis cannot be 
ruled out and merits further research in placebo- controlled studies 
with longer follow- up times and larger sample sizes. Also, we did not 
closely measure food consumption. The bitter taste of the ketone 
drink could have reduced appetite and food intake, which would 
alter glycaemia. However, the bitterness lasts for a few minutes and 
hunger reduction can also be directly attributed to elevated BHB 
blood levels.24
TA B L E  3 Plasma	and	anthropomorphic	cardiovascular	risk	




Triglycerides (mM) 1.18 ± 0.57 1.10	±	0.43
Cholesterol (mM) 5.35	±	1.3 5.84 ± 1.08
HDL (mM) 1.84 ± 0.54 1.84 ± 0.57
ApoB (mM) 0.9	±	0.3 0.9	±	0.3
C- reactive protein (mg/L) 2.1	±	0.9 1.9	±	0.9
Total weight (kg) 96.7	±	15.7 95.4	±	15.6
Total body fat % 33.2	±	6.6 33.0	±	6.6
Visceral fat % 12.4 ± 2.7 12.3	±	2.8
ALT (U/L) 41 ± 15 38	±	17
AST (U/L) 40 ± 14 38	±	15
NEFA (mM) 1.03	±	0.19 0.99	±	0.20
HOMA–	IRa  1.66	±	0.37 1.48 ± 0.45
10- year fatal CHD riska 	(%) 7.7	±	3.3 7.3	±	3.9
Note: Data are means ± standard deviations. All variables were 
compared against a baseline using a two- tailed paired Student's t- test. 
p was >.05 for all comparisons.
aHOMA and 10- year fatal coronary heart disease risk were calculated 
using an open access diabetes- specific calculator available at https://
www.dtu.ox.ac.uk/riske ngine/ downl oad.php
F I G U R E  1 The	effect	of	exogenous	ketosis	on	glycaemic	control	indicators.	(A)	Fructosamine	change	from	baseline	after	28	days	of	
consuming the ketone monoester. (B) HbA1c change from baseline after 28 days of consuming the ketone monoester. (C) Interstitial glucose 
daily	mean	difference	between	the	days	without	(weeks	1	and	6)	and	with	(weeks	2–	5)	ketone	monoester.	(D)	Time	in	range	difference	
between the days without and with ketone monoester. All variables were compared using a two- tailed paired Student's t- test. p was <.01 for 
all comparisons. n = 21
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Adherence	was	high	(>90%)	in	this	study,	possibly	because	all	
participants had tasted the bitter- tasting KE drink before being 
enrolled. However, it is possible that the taste could challenge its 
routine long- term consumption in a real- world setting. Finally, the 
KE drink is currently expensive on the free market, so it would 
be important to conduct cost- benefit studies. Nevertheless, these 
results are promising and warrant future placebo- controlled stud-
ies with sufficient statistical power to allow treatment- group 
comparisons.
5  |  CONCLUSIONS
These results confirm the safety and tolerability of three times daily 
KE drinks in patients with T2D. The KE drinks improved four mark-
ers of glycaemic control: HbA1c, fructosamine, mean glucose and 
time in range. Randomized clinical trials are needed to evaluate their 
clinical efficacy.
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